IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Their pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. 

Biotechnology

IO Biotech

Mai-Britt Zocca

Misbah Sherwani

Qasim Ahmad

Devin Smith

Eric Faulkner

Amy Sullivan

Brian Burkavage

Ayako Wakatsuki Pedersen

Margaret Siemon-Hryczyk

Dan Mannix

Diane Mcdowell

Muhammad Al-Hajj

The Leadership Team at IO Biotech is responsible for guiding the company's strategic direction and overseeing the development of innovative immune therapies for cancer treatment. This team integrates expertise in translational research and corporate leadership to drive the advancement of first-in-class therapies, ensuring alignment with the company's mission and maximizing the impact of their unique platform technology on patient outcomes.

Leadership Team

Research and Development

Regulatory and Clinical Operations

Clinical Operations Team

Leadership Team

About

Team members

Other teams at IO Biotech

Research and Development

Regulatory and Clinical Operations

Clinical Operations Team